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Background: PET radiopharmaceuticals capable of imaging β-amyloid (Aβ) plaque burden in the brain could
offer highly valuable diagnostic tools for clinical studies of Alzheimer’s disease. To further supplement existing
armamentarium of FDA-approved agents as well as those under development, and to correlate multiphoton-imaging
data reported earlier, herein, we describe preclinical validation of a PET tracer.
Methods: A novel PET radiopharmaceutical (18F-7B) was synthesized and characterized. To assess its affinity for
Aβ, binding assays with Aβ1-42 fibrils, Alzheimer’s disease (AD) homogenates, and autoradiography studies and
their IHC correlations were performed. For assessing its overall pharmacokinetic profiles in general and its ability
to cross the blood-brain barrier (BBB) in particular, biodistribution studies in normal mice were performed. Finally,
for evaluating potential for 18F-7B to serve as a targeted Aβ probe, the microPET/CT imaging was performed in
age-matched amyloid precursor protein/presenilin-1 (APP/PS1) mice and wild-type (WT) counterparts.
Results: The radiotracer 18F-7B shows saturable binding to autopsy-confirmed AD homogenates (Kd = 17.7 nM)
and Aβ1-42 fibrils (Kd = 61 nM). Preliminary autoradiography studies show binding of 18F-7B to cortical Aβ plaques
in autopsy-confirmed AD tissue sections, inhibition of that binding by unlabeled counterpart 7A-indicating specificity,
and a good correlation of tracer binding with Aβ immunostaining. The agent indicates high initial penetration
into brains (7.23 ± 0.47%ID/g; 5 min) of normal mice, thus indicating a 5-min/120-min brain uptake clearance
ratio of 4.7, a benchmark value (>4) consistent with the ability of agents to traverse the BBB to enable PET brain
imaging. Additionally, 18F-7B demonstrates the presence of parental species in human serum. Preliminary microPET/
CT imaging demonstrates significantly higher retention of 18F-7B in brains of transgenic mice compared with
their WT counterparts, consistent with expected binding of the radiotracer to Aβ plaques, present in APP/PS1
mice, compared with their age-matched WT counterparts lacking those Aβ aggregates.
Conclusions: These data offer a platform scaffold conducive to further optimization for developing new PET
tracers to study Aβ pathophysiology in vitro and in vivo.
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Alzheimer’s disease (AD) is the most frequent form of de-
mentia which affects 24 million people worldwide and also
lacks effective therapeutic interventions [1]. Without suc-
cessful treatment or prevention, the number of affected in-
dividuals can be expected to grow exponentially to 13 to 16
million in the United States and to >100 million globally by
2050. Overall healthcare cost in the United States alone in
2050 has been projected to be more than $1 trillion [2].
The failure of clinical drug trials to reverse clinical symp-
toms indicates that, for a given treatment to be effective, it
most likely needs to be prescribed at a preclinical stage be-
fore the symptomatic expression of the disease. Therefore,
there is an urgent need to identify and validate biomarkers
that are present at preclinical stages. Importantly, several
biomarkers identified for diagnosis, staging, and assessment
of therapeutic effects are (but not limited to): amyloid
deposition; changes in CSF levels of tau; hyperpho-
sphorylated tau (p-tau), or Aβ1-42; and reduced metabolism
monitored via fluorodeoxyglucose (FDG) PET imaging
[3–6]. While amyloid deposition and variations in CSF
levels of tau and Aβ represent pathophysiological markers
thus relevant for disease diagnosis, the reduced metabolism
(FDGPET) or atrophy (MRI) demonstrate topographic
markers indicating a progression of the disease. Further-
more, literature precedents of the last decade indicate that
AD pathological changes (Aβ deposition and NFT forma-
tion) occur years prior to onset of symptoms [7]. For diag-








furan-6-ol(18F-AZD4694) [12, 13] have been investigated in
humans. In addition, [125I/131I]TZDM and [125I]IMPY have
also been investigated for SPECT applications [9]. While
[11C]PIB has been most intensely studied, [18F]Avid45
(Amyvid) [14], 18F-Flutemetamol (Vizamyl) [15, 16], and
Florbetaben (Neuraceq™) [17–19] have been recently ap-
proved by FDA for Aβ imaging. Importantly, both Amyvid
[20] and [11C]PIB show promising results in humans and
excellent correlation with FDG [8]. Recent investigations
using PIB and Amyvid [21] binding to AD homogenates
also indicate multiple binding sites on Aβ [22], thus
mandating development of new tracers to study Aβ
pathophysiology. To further supplement the existing
armamentarium of FDA-approved Aβ-imaging agents; re-
cently, we have shown that a heterocyclic fluorescent mol-
ecule 7A is able to traverse the blood-brain barrier (BBB) to
label Aβ plaques in brains of APP+/−/PS1+/− mice and also
labels diffuse plaques in autopsy-confirmed AD humantissues [23, 24]. Herein, we report synthesis and
characterization of (E)-5-(2-(6-(2-[18F]-fluoroethoxy)-ben-
zo[d]thiazol-2-yl)vinyl)-N,N-dimethylpyridin-2-amine, an
F-18-labeled counterpart (18F-7B), and perform its preclin-
ical validation to evaluate its potential to serve as an Aβ-
targeted PET radiopharmaceutical for monitoring plaque
burden in AD.
Methods
All reagents were purchased from Sigma-Aldrich unless
otherwise stated. 2-fluoroethyl-4-methylbenzene sulfonate
was prepared using literature procedure [25]. 1H NMR,
proton-decoupled 13C NMR, and 19F NMR spectra were
recorded on a Varian 400-MHz spectrometer; chemical
shifts are reported in δ (ppm) with reference to either
TMS or trichlorofluoromethane (CFCl3). Mass spectra
were obtained from the University of Missouri Mass
Spectrometry facility using nitrobenzyl alcohol (NBA)
as matrix and analyzed via HRFab. Purity of the 7A and
7B were assessed using an HPLC (Waters system 600
equipped with dual λ-detector 2487 set to 254 and 280
nm) with a C-18 reversed-phase column (Phenomenex
Luna® C18; 100 Å; 5 μm; 250 × 10 mm) using an eluent
mixture of acetonitrile and water as a gradient system (75%




To the mixture of 6-methoxy-2-methyl benzothiazole (1.0
mmol) and 6-dimethylamino pyridine carbaldehyde (1.0
mmol) in DMSO was added 50% KOH and stirred at room
temperature for 12 h. After the completion of the reaction,
the reaction mixture was filtered, and the yellow solid ob-
tained was used for the next reaction without purification.
Yield 92% (0.28 g); yellow solid; Rf 0.62 (3:2 hexane-
EtOAc); 1H NMR (400 MHz, CDCl3 ): 3.15 (s, 6H), 3.88 (s,
3H), 6.55 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 7.14
(d, J = 16.0 Hz, 1H), 7.29 (t, J = 14.0 Hz, 2H), 7.71 (d,
J = 8.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 8.29 (s, 1H); 13C
NMR (100 MHz, CDCl3): 38.14, 55.79, 104.13, 106.05,
115.31, 118.0, 119.41, 123.02, 134.08, 134.22,148.93, 159.15,





The condensed product (0.28 g, 1.0 mmol) was taken in a
50-mL RB, dissolved in dry DCM under argon and sub-
jected to −78°C using dry ice/acetone bath and stirred for
5 min. BBr3 (1 M in DCM, 5 mL, 5.0 mmol) was added
drop wise maintaining the same temperature. The result-
ing mixture was slowly brought to room temperature and
stirred overnight. The completion of the reaction was
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flask is cooled to 0°C before addition of cold satd. sodium
bicarbonate solution (5 mL). The reaction mixture is then
extracted with ethyl acetate (4 × 25 mL), washed with
water (2 × 50 mL), dried over anhydrous sodium sulfate,
and the solvent evaporated under reduced pressure to give
the red solid which was further purified by flash chroma-
tography using hexane:EtOAc:MeOH (10:9:1) as eluent.
Yield 86% (0.27 g); light red solid; Rf 0.24 (1:1 hexane-
EtOAc);1H NMR (400 MHz, CDCl3): 3.03 (s, 6H), 6.65 (d,
J = 8.4 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 7.24 to 7.32 (m,
2H),7.66 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 7.6 Hz, 1H), 8.29
(s, 1H), 9.82 (s, 1H); 13C NMR (100 MHz, CDCl3): 38.04,
106.51, 107.08, 116.11, 118.03, 119.58, 123.17, 134.13,
134.96, 135.60, 147.47, 149.36, 155.90, 159.25, 163.97;





To the solution of alcohol (0.15 g, 0.4 mmol) and 2-
(Bromoethoxy)-tert-butyldimethylsilane (0.096 g, 0.4
mmol) in DMF (5 mL) was added Cs2CO3 (0.20 g, 0.6
mmol). The resulting mixture was stirred at 140°C for 6 h.
Following the completion of the reaction (monitored by
TLC), it was quenched with the addition of ice cold
water and extracted with ethyl acetate (3 × 25 mL). The
organic layer was washed with water (2 × 50 mL) and
dried over anhydrous sodium sulfate and the solvent
evaporated under reduced pressure to give crude prod-
ucts which were purified by PTLC using hexane:EtOAc
(60:40) as eluent; yield 54% (0.12 g); yellow solid; Rf
0.44 (2:3 hexane-EtOAc); 1H NMR (400 MHz, CDCl3):
0.12 (s, 6H), 0.92 (s, 9H), 3.15 (s, 6H), 4.02 (bs, 1H),
4.11 (bs,1H), 6.56 (d, J = 8.8Hz, 1H), 7.06 (d, J = 8.4
Hz, 1H), 7.14(d, J = 16.4 Hz, 1H), 7.24 to 7.32 (m, 2H),
7.72 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.8 Hz, 1H), 8.29
(s, 1H); 13C NMR (100 MHz, CDCl3): 31.04, 42.24, 68.44,
76.22, 110.76, 112.22, 121.21, 124.34, 129.86, 140.02,
142.74, 149.96, 152.44, 162.68, 172.86; HRMS (FAB) m/z
calc. for C24H34N3OSSi: [M]




To the solution of TBDMS-protected compound (0.05 g,
0.1 mmol) in THF was added TBAF (1 M in THF, 0.5 mL,
0.5 mmol) and stirred at RT for 6 h. Following completion
of the reaction (monitored by TLC), the solvent was evapo-
rated under reduced pressure to obtain a crude product
which was purified by PTLC using hexane:EtOAc (75:25) as
eluent. 1H NMR (400 MHz, CD3COCD3): 3.17 (s, 6H), 3.96
(bs, 2H), 4.20 (bs, 2H), 6.65 (d, J = 8.9, Hz, 1H), 6.71 (d, J =
8.8 Hz, 1H), 7.10 (t, J = 8.2 Hz, 1H), 7.23 (d, J = 16.4 Hz,1H), 7.43 (d, J = 16.4 Hz, 1H), 7.57 to 7.93 (m, 2H), 8.36
to 8.42 (m, 1H) 13C NMR (100 MHz, CD3COCD3 ):
37.08, 60.41, 70.33, 104.64, 105.07, 105.82, 115.79,




Pyridine (0.08 g, 1 mmol) and DMAP (0.0012 g, 0.01
mmol) were added to a solution of alcohol (0.08 g, 0.2
mmol) in DCM (10 mL) at 0°C. Thereafter, p-toluene-
sulfonylchloride (0.076 g, 0.4 mmol) dissolved in DCM
(2 mL) was added, and the resulting solution was stirred
at room temperature for 7 h and quenched by the
addition of water (15 mL). The resulting mixture was ex-
tracted with DCM (3 × 5 mL), and organic extracts were
combined, dried over Na2SO4, filtered, and concentrated.
Finally, the residue was purified by Prep TLC using the
eluent mixture (Hex/EtOAc = 60:40) to obtain the com-
pound as a viscous yellow liquid. Yield 57% (0.06 g);
yellow viscous liquid; Rf 0.41 (1:1 hexane-EtOAc): 1H
NMR (400 MHz, CDCl3): 2.43 (s, 3H), 3.15 (s, 6H), 4.22
(m, 2H), 4.41 (bs, 2H), 6.52 (d, J = 8.4 Hz, 1H), 6.54 (d,
J = 8.4 Hz, 1H), 6.68 (d, J = 12.6 Hz, 1H), 6.81 (d, J = 12.6
Hz, 1H), 6.91(d, J = 8.8 Hz, 1H), 7.08 to 7.17 (m, 1H), 7.30
to 7.34 (m, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 9.6
Hz, 1H), 7.83 (d, J = 9.6 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H),
8.31 (d, J = 10.0 Hz, 1H) 13C NMR (100 MHz, CDCl3 ):
21.63, 38.08, 66.08, 67.99, 104.97, 105.05, 106.05, 115.53,
115.68, 117.82, 120.96, 123.03, 123.46, 127.97, 129.84,
134.10, 134.27, 134.45, 137.89, 144.99, 148.98, 149.76,
156.02. HRMS (FAB) m/z calc. for C25H25N3O4S2Na:
[M]+ + Na 518.1184; found: 518.1176.
(E)-5-(2-(6-(2-fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-
dimethylpyridin-2-amine (7A)
Dry tetrabutylammonium fluoride (0.065 g, 0.25 mmol)
was dissolved in dry acetonitrile (5 mL) under argon and
treated with the acetonitrile solution of tosylated precur-
sor 6 (0.050 g, 0.1 mmol) and refluxed at 110°C. The
progress of the reaction was monitored via the TLC.
Following completion of the reaction, the solvent was
evaporated, and the residue was extracted with EtOAc
(2 × 10 mL). Combined organic extracts were dried with
Na2SO4, filtered, and evaporated, and the residue was
purified using thin-layer chromatography employing a
mobile eluent mixture (Hex:EtOAC = 80:20) to obtain 7A
(0.021 g; 60%; bright yellow solid; Rf = 0.42; 3:2, EtOAc-
hexane).1H NMR (400 MHz, CDCl3): δ 3.14 (s, 6H), 4.20
to 4.33 (m, 2H), 4.79 (dd, J = 47.6, 8.0 Hz, 2H), 6.51 to
6.57 (m, 1H), 6.67 to 6.82 (m, 1H), 7.08 (dd, J = 9.2, 2.6
Hz, 1H), 7.23 to 7.34 (m, 1H), 7.30 to 7.34 (m, 1H), 7.70 to
7.97 (m, 2H), 8.31 (dd, J = 8.8, 2.0 Hz 1H); 13C NMR (100
MHz, CDCl3 ): δ 38.10, 38.13, 67.63, 67.84, 81.01, 82.70,
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134.33, 148.98, 156.36, 159.17, 165.74; 19F NMR (282
MHz, CFCl3 ): −224 ppm; HRMS (FAB) m/z calc. for C18
H19 FN3 OS: [M + 1]
+ 344.1232; found: 343.1230.
Radiochemical synthesis 18F-7B
For radiolabeling, tosylated precursor (5, 3 mg) dissolved
in dry acetonitrile (400 μL) was transferred into an amber-
colored vial containing anhydrous kryptofix 2, 2, 2 (Sigma
Chemicals, Perth, WA, AU)/K2CO3/
18F-fluoride, obtained
using standard procedures. The reaction mixture was
heated to 100°C for 20 min in an oil bath, cooled in ice-
cold water, and diluted to 5% acetonitrile in water. The
crude mixture was loaded on a C-18 sep-Pak cartridge
(Waters, Milford, MA, USA), primed with ethanol (5 mL)
and water (10 mL). The C-18 sep-Pak was washed with
water (5 mL × 6) and 25% acetonitrile (5 mL × 4) and
finally eluted with 100% acetonitrile (1 mL).
The crude mixture was purified using high-performance
liquid chromatography (dual λ detection set at 254 and
280 nm) equipped with a radiodetector (Bioscans) using a
C-18 column (Phenomenex (Torrance, CA, USA); 5-μm
250 × 10 mm) using an eluent gradient acetonitrile 75% to
95% over 20 min (flow rate: 3 mL/min). The fraction of
18F-7B eluting at 9.5 min (radiochemical purity >95%;
radiochemical yield: 30%; specific activity: 1,200 to 1,400
Ci/mmol) was collected, concentrated, resuspended in
ethanol/saline, and employed for bioassays.
Metabolite analysis
Human serum (Sigma-Aldrich, St. Louis, MO, USA) was
thawed. Serum (100 μL) was taken, diluted with saline to
10%, and incubated with HPLC-purified fraction of 18F-7B
(100 μCi each) at 37°C for 30 and 60 min. Samples were
periodically withdrawn and analyzed on radio-HPLC using
eluent mixture described above and radio-TLC using an
eluent mixture of ethanol/saline in a ratio of 90:10 (to allow
mobility of parental compound and other hydrophobic
metabolites off the surface to analyze protein binding) and
10:90 (to analyze hydrophilic metabolites).
Preparation of human brain homogenates
Well-established literature procedures were used for
preparation of AD homogenates [11, 26]. Grey matter
was isolated from frozen postmortem frontal cortex tis-
sue by dissection with a scalpel. To prepare insoluble
fractions, dissected tissue was sequentially homogenized
in four buffers (3 mL/g wet weight of tissue) with glass
dounce tissue grinders (Kimble, Vineland, NJ, USA): 1)
high salt (HS) buffer: 50 mM Tris-HCl pH 7.5, 750 mM
NaCl, 5 mM EDTA; 2) HSbuffer with 1%Triton X-100;
3) HSbuffer with 1%Triton X-100 and 1 M sucrose; and
4) phosphate-buffered saline (PBS). Homogenates were
centrifuged at 100,000×g; after each homogenizationstep, the pellet was resuspended, and homogenized in
the next buffer in the sequence. For comparison in initial
binding studies, unfractionated tissue homogenates were
also prepared by homogenization of tissue in only PBS.Preparation of Aβ1-42 fibrils
Aβ1-42 fibrils were obtained using literature procedures
described earlier [26]. Briefly, synthetic Aβ1-42 peptide
(1 mg) (Bachem, Torrance, CA) was initially dissolved in
DMSO (50 μL) and diluted with the addition of mQ-H2O
(925 μL). Finally, 1 M Tris-HCl (25 μL; pH 7.6) was added
to the peptide solution to obtain a final peptide concentra-
tion (222 μM; 1 mg/mL) [27]. Thereafter, the peptide solu-
tion was incubated for 30 h at 37°C with shaking at 1,000
rpm in an Eppendorf Thermomixer. The fibril formation
was confirmed by ThioT fluorescence. For determining
the concentration of fibrils, the fibril reaction mix was
centrifuged at 15,000×g for 15 min to separate the fibrils
from the monomer. The concentration of Aβ monomer in
the supernatant was determined in a BCA protein assay.Binding assays
Binding assays were performed using previously described
methods [26]. Briefly, a fixed concentration (1 μM/well) of
Aβ1-42 fibrils was incubated for 1 h at 37°C with increasing
concentrations of 18F-7B (1.5 to 100 nM) in 30 mM Tris-
HCl pH 7.4, 0.1% BSA in a reaction volume of 150 μL. A
fixed ratio of hot:cold (18F-7B and 7A) was used for all
radioligand concentrations. The exact hot:cold (18F-7B:7A)
ratio was measured in each experiment by counting an
aliquot of a sample (2 μL) of the radioligand preparation in
a scintillation counter. Binding of 18F-7B to human brain
homogenates was assessed by incubating samples of insol-
uble fraction (5-μg insoluble protein/well) from AD
subjects, with increasing concentrations of 18F-7B (1.5 to
100 nM). Nonspecific binding was determined in parallel
experiments utilizing 7A (2.5 μM) for Aβ1-42 fibrils and
7A (5 μM) for AD tissue as a competitor. Bound and free
radioligand were separated by vacuum filtration through
glass fiber 96-well filter plates (Millipore Multiscreen FB
filter plate), followed by washes using ice-cold assay buffer
(3 × 150 μL). Glass fiber filters containing the bound lig-
and were mixed with Optiphase Supermix scintillation
cocktail (150 μL; PerkinElmer, Waltham, MA, USA) and
counted immediately. All data were obtained in triplicate
and analyzed by curve fitting to a one-site binding model
using nonlinear regression employing Graphpad Prism
software (version 4.0) to determine Kd and Bmax values.
Bmax values were calculated in pmol/gram wet weight of
brain tissue [28]. To calculate binding potential (BP)
where BP = Bmax/Kd, Bmax was converted from pmol/gram
brain tissue to units of nanomolar by assuming 1 g of
brain tissue = 1 mL [28].
Sundaram et al. EJNMMI Research  (2015) 5:33 Page 5 of 13Autoradiography and immunohistochemistry
Frozen AD frontal cortex sections (12 μm) were
obtained using a TBS Minotome PLUS Cryostat. The
tissue sections were thaw-mounted onto Superfrost Plus
(Fisherbrand 12-550-15 (Fisherbrand, Leicestershire,
UK)) microscope slides, allowed to air dry for 10 to 15
min, and stored at −80°C. For autoradiography, brain
sections were brought to room temperature for 5 min
and then pre-incubated in assay buffer (30 mM Tris-
HCl, pH 7.4 + 0.1% BSA) for 10 min at RT. Sections
were incubated with 18F-7B (300 μL/slide; 10 nM) in the
assay buffer for 60 min at room temperature. For deter-
mining nonspecific binding, adjacent sections were incu-
bated in the additional presence of 2.5 μM cold ligand 7A.
Sections were then washed at RT for 1 min in 30 mM
Tris-HCl pH 7.4, 2 min in 70% ethanol/30 mM Tris-HCl,
1 min in 30% ethanol/30 mM Tris-HCl, and 1 min in
30 mM Tris-HCl (washing protocol using literature prece-
dents [29]. Sections were then dried and exposed to
phosphor-imaging screen (BAS-MS 2025) for 30 min.
Autoradiography images were obtained on a Fuji Bio-
Imaging System FLA-7000 (Tokyo, Japan) and analyzed
using MultiGauge software (Fuji, Tokyo, Japan). Follow-
ing exposure to a phosphor-imaging screen, the sections
were then blocked for 60 min at room temperature with
3% milk-0.25% Tween 20-PBS buffer. Immunostaining for
Aβ plaques was carried out using monoclonal antibody
HJ3.4 (directed against the N-terminus of human Aβ)
conjugated to Alexa 568 (generously provided by John
Cirrito). The sections were incubated overnight in anti-
body diluted 1:250 in 0.5% milk-PBS-0.25% Tween 20
at 4°C, washed for 5 min × 3 with PBS-0.25% Tween 20,
and air dried [30, 31]. Finally, sections were cover-
slipped and scanned with the NanoZoomer 2.0-HT System
(Olympus) at 20× resolution using TRITC fluorescence
filter, and images were acquired using NDP scan 2.5
software (Olympus).Biodistribution studies
All animal procedures were approved by the Washington
University Animal Studies Committee. Pharmacokinetics
of 18F-7B in brain and other critical tissues of normal male
12-week-old FVB (wild type (WT); 28 to 36 g) mice were
determined as previously described [32]. Briefly, 18F-7B
(740 kBq) was dissolved in 100-μL saline containing 10%
ethanol. All animals were anesthetized by isofluorane in-
halation and injected with radiotracer 18F-7B (740 kBq,
100 μL) via bolus injection through a tail vein. Animals
were sacrificed by cervical dislocation under anesthesia at
5, 30, 60, and 120 min after injection (n = 3 each). Blood
samples were obtained by cardiac puncture, organs then
harvested rapidly, and all tissue samples analyzed for
γ-activity. Data are expressed as the percentage injecteddose (%ID) per gram of tissue (tissue kBq (injected kBq)−1
(g tissue)−1 × 100).
MicroPET/CT imaging
For imaging, female double-transgenic mouse (BL6/FVB
APP/PS1, 22.6 months old, n = 3) and a female wild-
type mouse (BL6/FVB; 22.6 months old, n = 3) were
anesthetized with isoflurane (1.5% to 2.5%) in oxygen at
flow rate of 1 to 2 L/min via an induction chamber and
maintained with a nose cone. Following anesthesia, the
mice were secured with their heads in the center of the
field of view, fixed in the scanner in a prone head-first
position (HFP), and placed in an acrylic-imaging tray.
MicroPET imaging was performed using Inveon PET/
CT scanner (Siemens Medical Solutions, Malvern, PA,
USA) following intravenous tail-vein injection of HPLC-
purified [18F]7B (12.95 MBq; 28 μL; 35% ethanol in sa-
line) employing the catheter system in a slow bolus,
followed by flushing with isotonic saline solution. PET
dynamic data acquisition was performed over 75 min
starting immediately following injection of the tracer.
The emission data were normalized and corrected for
attenuation, scatter, and decay. Attenuation correction
was obtained using the co-registered CT data. The
image volume consisted of 256 × 256 × 159 voxels, with
a size of 0.39 × 0.39 × 0.8 mm3 per voxel for the Inveon
scanner. For anatomical visualization, PET images were
co-registered with CT images from an Inveon PET/CT
scanner. For analysis, brain uptake (Bq/L) was normal-
ized to injected dose and weight of animals. For analysis,
PET images were initially reconstructed in 52 dynamic
frames and the second time as four frames of 30 min
each, with 3D-MAP reconstruction algorithm for in-
corporating resolution recovery (20 iterations, β value of
0.0043). For evaluation of uptake ratios of cortex and
cerebellum, the regions of interest (ROI) were drawn in
the frontal cortex (target) and cerebellum (reference)
regions in both transgenic and WT mice. Additionally,
SUV values in time-activity curves were normalized to
the average activity measured in those regions between 1
to 2 min post-injection. All image data were processed
and analyzed using Inveon Research Workspace 4.1 soft-
ware (Siemens, Malvern, PA, USA). All PET and CT
image datasets were scaled to calibrated kBq/cc.
Results and discussion
For synthesis, 6-methoxy-2-methylbenzothiazole 1 was ob-
tained using literature procedures [23, 33] and condensed
with 6-(dimethyl-amino)-nicotinaldehyde in an aqueous
potassium hydroxide (50%) solution dissolved in DMSO to
obtain 2. Following purification, 2 was demethylated in the
presence of BBr3 to yield the phenolic derivative 3. Further,
3 was alkylated with 2-bromoethoxy-t-butyl-dimethylsilane
in the presence of cesium carbonate to obtain t-butyl-
Figure 1 Radio-HPLC data of purified [18F]-7B spiked with an
unlabeled counterpart (7A) for characterization of the radiotracer (7B).
Sundaram et al. EJNMMI Research  (2015) 5:33 Page 6 of 13dimethylsiloxy-ethoxy intermediate 4. Following treatment
with TBAF, the intermediate yielded the corresponding
ethanol derivative 5. Upon treatment with p-toluene
sulfonylchloride, final precursor ligand 6 was obtained
(Scheme 1). While the unlabeled counterpart 7A was
obtained by treatment of precursor ligand 6 with TBAF,
the no-carrier-added counterpart PET-tracer 18F-7B was
obtained via standard nucleophilic substitution, using a
well-established krytofix/18F methodology. While all inter-
mediates 1, 2, 3, 4, 5, and 6 were characterized via routine
analytical methods, the 18F-7B was characterized via co-
injection with a well-characterized sample of its unlabeled
counterpart 7A (Figure 1). The PET tracer 18F-7B eluted
as a single chemical entity (radiochemical purity >95%),
with a retention time of 9.5 min on a semi-preparative
HPLC column (Phenomenex Luna® C18; 100 Å) (5 μm,
250 × 10 mm; flow rate, 3 mL/min). The appropriate
fraction eluting at 9.5 min was collected, concentrated,
dissolved in 10% ethanol in saline, and employed for
bioassays (specific activity: 1,200 to 1,400 Ci/mmol). Al-
though brain-imaging agents post-intravenous injection
are known to show extremely facile penetration within
the brain, nevertheless, permeation of competing la-
beled entities could complicate analysis. To assess pre-
liminary stability in vivo, 18F-7B was incubated in human
serum at 37°C up to 60 min, and radio-HPLC indicated
the presence of primarily the parental compound. Of note,
radio-HPLC detects the presence of mobile species
thereby allowing immobile species to be retained on the
column. Therefore, both radio-HPLC and radio-TLC have
been used to allow detection of both polar and nonpolarScheme 1 Preparation of the precursor ligand, parental unlabeled ligand (radiometric metabolites. The radio-TLC demonstrated the
presence of the single radiometric peak thus consistent
with presence of 18F-7B under these conditions. Overall,
the correlation of radio-HPLC and radio-TLC data in-
dicated the metabolic stability of 18F-7B in the human
serum under these conditions.
For assessing the ability of 18F-7B to bind Aβ plaques,
preliminary binding assays with either preformed Aβ1-42
aggregates or AD homogenates were performed in PBS.
Nonspecific binding was determined in the presence of
7A (5 μM) as a competitor. Overall, the binding assay of
18F-7B with AD homogenates (Figure 2) indicates a sat-
urable specific binding (Kd = 17.7 nM; Bmax = 1,4327A), and its no-carrier-added counterpart ([18F]-7B).
Figure 2 Binding of [18F]-7B with Aβ1-42 fibrils and AD homogenates.
AD homogenates (A, B) and Aβ1-42 fibrils (C, D) were incubated with
increasing concentrations of [18F]-7B. Nonspecific binding was
determined in parallel experiments utilizing 7A (5 μM) as a competitor.
Representative plots of specific binding versus [18F]-7B concentration
are shown for AD homogenates in (A) and Aβ fibrils in (C). Data points
represent mean ± standard deviations (n = 3). The data were analyzed
by curve fitting to a one-site binding model using a nonlinear regression.
Scatchard plots of the binding data are shown for AD homogenates
(B) and Aβ1-42 fibrils (D). Similar results were obtained in more than
three independent experiments.
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affinity of 18F-7B with preformed fibrils (Kd = 61 nM;
Bmax = 6 pmol/nmol Aβ; Figure 2c,d) is nearly identical
to the Kd value (59 nM) of 7A reported earlier [23].
Thus, the radiotracer binding assay technique shows a
very close correlation with that of the fluorescence assay
indicating identical binding properties of both the
labeled and unlabeled counterparts. Furthermore, 18F-7B
shows 3.4-fold higher affinity for AD homogenates com-
pared with that of fibrils, a promising trait of translatable
agents. Importantly, binding affinity of 18F-7B to AD
homogenates is 2.6- and 5-fold lower than the FDA-
approved radiotracers Flutemetamol [16] and Florbetapir
[11], respectively. Furthermore, binding affinity of 18F-7B
is fairly close to that of Florbetaben (Kd: 16 nM), the other
FDA-approved radiotracer. However, it can also be argued
that any advantage or disadvantage of a given imaging
agent attributed only to the binding affinity is also equally
dependent upon levels of occurrences of a given bio-
marker (that could be present either in very low or very
high concentrations) in the targeted tissue [34]. One of
the guiding principles for designing optimal brain-imaging
agents also involves attaining a binding potential (BP)
Bmax/Kd ratio ≥10, although a lower value of BP could also
enable PET molecular-imaging applications [22, 34, 35].
Given the high concentration of potential Aβ plaques and
associated binding sites in AD brain [34], this could also
mean that a radioligand with a Kd value of approximately
18 nM (BP (a combined measure of receptor density and
affinity) = 1,432 nM/18 nM = 80) may be sufficient for
imaging Aβ in AD. However, it is quite possible that the
concentration of potential Aβ binding sites in earliest or
presymptomatic AD brain is 1 order of magnitude less
than 1,400 nM. Therefore, high-affinity ligands could offer
better alternatives specifically when high-affinity binding
sites predominate in the cortex and hippocampus of AD
homogenates and are absent in the cerebellum [21].
Further analysis of BP of 18F-7B indicates that its value of
80 (in homogenates) is also 6- and 2-folds lower than that
of 11C-PIB (Bmax: 1,407 nM; Kd: 2.5 nM; BP: 563) [28] and
18F-Florbetaben (Bmax: 2,431 nM; Kd: 16 nM; BP: 152),
respectively [36]. Combined results of binding affinity data
suggest that PET-imaging characteristics of 18F-7B could
Sundaram et al. EJNMMI Research  (2015) 5:33 Page 8 of 13be slightly inferior to that of Flutemetamol and Florbetapir.
Further, to evaluate the ability of 18F-7B for labeling Aβ in
autopsy-confirmed human brain sections, autoradiography
and immunohistochemical correlations were also per-
formed. Following incubation of AD frontal cortex
sections (12 μm) with 18F-7B (10 nM) for 60 min, the
agent showed labeling of cortical Aβ plaques, and the
binding was inhibited upon incubation in the pres-
ence of 7A (2.5 μM) (Figure 3a,c). These data indicate
sensitivity and specificity of the 18F-7B. Additionally,Figure 3 Autoradiography images and fluorescent immunostaining. Autora
following incubation with [18F]-7B (10 nM) alone (A) or in the presence of
with an anti-Aβ antibody is shown in (B) and (D), respectively. The autorad
in cortex (bracket and arrows), which correlates with the distribution of Aβ pla
inhibited by excess cold ligand (C). The higher nonspecific binding in the lowimmunohistochemical staining of these sections using
anti-Aβ antibody indicated the presence of Aβ plaques in
the cortex of these sections (Figure 3b,d), thus demon-
strating excellent correlation of immunohistochemical
staining data with that of autoradiography data. However,
nuclear imaging of a given biomarker in vivo is a net func-
tion of signal to noise and thus also equally dependent
upon pharmacokinetics of a given radiotracer in vivo.
Recently [23, 24], we have demonstrated via multipho-
ton imaging that 7A could traverse the BBB to labeldiography images of [18F]-7B binding in an AD frontal cortex section
7A (2.5 μM) (C). Fluorescent immunostaining of sections (A) and (C)
iography images demonstrate laminar distribution of [18F]-7B binding
ques shown by fluorescent immunostaining, and binding of [18F]-7B is
er left region (A) is due to folding of the tissue section.
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However, doses used for fluorescence were several folds
higher than required for PET-imaging applications
in vivo. Therefore, to assess whether or not PET coun-
terpart 18F-7B administered at tracer concentrations
relevant for nuclear imaging also displays similar kinetics
in vivo, its pharmacokinetic studies in normal mice and
microPET-imaging studies in transgenic mice and WT
counterparts were performed. To accomplish this object-
ive, biodistribution studies of 18F-7B were performed in
normal FVB mice for preliminary assessment of signal-
to-noise ratios and its clearance profiles. Uptake in brain
and other critical organs was analyzed in terms of per-
cent injected dose per gram of the tissue (%ID/g) Table 1.
For in vivo imaging of Aβ plaques, the basic pharmaco-
kinetic model in normal brains involves a high initial
penetration of the agent, followed by facile clearance
due to lack of a binding target. Preliminary biodistribu-
tion studies (Table 1) with HPLC-purified 18F-7B in nor-
mal mice show transient brain uptake values of 7.23 ±
0.47%ID/g and 1.55 ± 0.01%ID/g, 5- and 120-min post
tail-vein injection, respectively, thus providing a 5 min/
120 min clearance a ratio of 4.66. For comparison, brain
uptake ratios of Florbetapir (2 min/2 h) and Florbetaben
(2 min/4 h) in normal mice are 4.07 (%ID/g (brain): 2
min: 7.33 ± 1.54; 2 h: 1.80 ± 0.07; 7.33/1.80; 4.07) [11]
and 5.0 (%ID/g (brain): 2 min: 4.77; 4 h: 0.95; 4.77/
0.95; 5.02) [37], respectively. Therefore, the brain up-
take clearance ratio of 18F-7B (5 min/120 min) is
slightly superior to Florbetapir and comparable to that
of Florbetaben in healthy mice. For an agent to be able
to serve as an Aβ-imaging agent, literature precedents
indicate that brain uptake ratio (%ID/g; the earliest
time point; 2 to 5 min to that of the latest time point;
typically for carbon-11; 30 to 60 min; and F-18, 2 h) of
3.5 or above could be considered as a benchmark for
the ability of a given agent to cross the blood-brain
barrier [38]. Additionally, brain uptake of a given im-
aging agent is a net function of several components,
such as cerebral regional blood flow, BBB permeability,
plasma radiotracer concentration, and free fractions of
the radiotracer in plasma and in the brain. Additionally,
the lipophilicity of a given compound reflects criticalTable 1 Biodistribution data (%ID/g) of [18F]-7B in FVB
mice (n = 3)
Organ (%ID/g) 5.00 min 30.00 min 60.00 min 120.00 min
Blood 3.18 ± 0.23 2.51 ± 0.09 2.40 ± 0.17 1.86 ± 0.05
Brain 7.23 ± 0.47 2.27 ± 0.13 2.00 ± 0.15 1.55 ± 0.01
Bone 1.61 ± 0.20 2.08 ± 0.13 3.41 ± 0.37 5.27 ± 0.34
Liver 16.22 ± 1.43 5.21 ± 0.08 3.44 ± 0.20 2.73 ± 0.16
Kidney 6.72 ± 0.44 2.83 ± 0.09 2.20 ± 0.07 1.59 ± 0.03
%ID, percentage injected dose.physicochemical trait for neuroimaging radiotracers due
to its direct relationship to membrane permeability, solu-
bility in water, and entropic contribution to binding. Lit-
erature precedents indicate that lipophilic drugs readily
cross the BBB, although other chemical characteristics, in-
cluding the number of hydrogen bonds, molecular weight,
polar surface area, and molecular size, are also known to
be critical to passive transport. Lipophilicity measured via
LogPOCT, the partition coefficient for nonionized mole-
cules between octanol and water, is a good indicator of a
molecule to permeate the brain, and molecules possessing
Log P values of 0.9 and 3.0 have been shown to cross the
BBB [39]. Conversely, radiotracers that are too lipophilic
can also bind plasma proteins and undergo fast metabol-
ism and also display high nonspecific binding. 18F-7B
demonstrates a log P value of 1.3 which is identical to that
of PIB (1.3) but considerably lower than that of Florbetapir
(2.4) and Florbetaben (3.22). The clearance ratio of 4.66
(%ID/g; 5 min/120 min; Table 1) provides further evidence
for the ability of the radiotracer to traverse the BBB in vivo
and is consistent with previous data using multiphoton
imaging [23]. Additionally, the agent 18F-7B showed ex-
cretion from other critical organs over 2 h and slight
defluorination as a function of time indicated by bone ac-
cumulation thus consistent with pharmacokinetic profiles
of other FDA-approved agents [11, 15, 16].
Transgenic mice expressing mutated forms of the
gene for the human amyloid precursor protein (hAPP)
show a marked elevation in Aβ-protein levels and their
deposition in the cerebral cortex and hippocampus
[40], which represent neuropathological hallmarks simi-
lar to those observed in human AD brains. It is also
noteworthy that presenilin-1 (PS1) mutant transgenic
mice show increased Aβ1-42 peptide formation, thus
augmenting amyloid deposition in Tg2576 APP mice at
6 months of age [41]. Therefore, the double-transgenic
mice having co-expression of these mutated genes
(APP+/−/PS1+/−) exhibit a strikingly accelerated accu-
mulation of Aβ deposits compared with the single APP
transgenic counterparts [42, 43]. Noticeably, several Aβ li-
gands [44–46] and disease-modifying therapeutics have
been investigated for their efficacy using APP+/−/PS1+/−
transgenic models [47, 48]. Previously, we have shown via
multiphoton imaging the pharmacokinetics of 7A in
brains of transgenic mice at the highest resolution and its
ability to penetrate the BBB to label Aβ plaques in brain
parenchyma and blood vessels (CAA) [23]. Additionally,
the low level of background fluorescence from residual re-
tention of 7A in nearby brain regions suggested high
signal-to-background ratios thus desirable of PET imaging
in vivo. While fluorescence imaging offers high-resolution
spatial localization of an imaging probe within a narrow
field of view, the PET imaging provides its assessment at a
relatively lower resolution within the whole organ.
Figure 4 MicroPET/CT imaging. APP/PS1 and WT mice (22.6 months old; n = 3; closely age-matched) were injected intravenously with HPLC-purified
[18F]-7B (12.95 MBq). Representative PET static images of brain (axial and coronal view) were obtained from 1- to 75-min post-intravenous injection and
co-registered with CT for an anatomical reference. (A) Axial and coronal images of the transgenic and wild-type mice post-intravenous injection of the
radiotracer. (B) Axial and coronal images of the transgenic and wild-type mice 15- to 45-min post-intravenous injection of the radiotracer Left: APP/PS1
mouse; Right: WT mouse. Note consistent higher retention of [18F]-7B in the brains of APP/PS1 (Left) compared with WT counterpart (Right). APP,
amyloid precursor protein; PS1, presenilin-1; WT, wild type.
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radiotracer for detecting Aβ in vivo at concentrations rele-
vant for clinical nuclear imaging. To directly access the
potential of 18F-7B to bind Aβ plaques in vivo, we per-
formed microPET/CT imaging in age-matched APP
+/−/PS1+/− mice (n = 3) compared to their WT counter-
parts, 5-min to 2-h post tail-vein injection. For any given
agent to serve as an Aβ-targeted agent, a pharmacokinetic
model would involve an initial high and equal influx of the
tracer into the brains of transgenic and WT mice, followed
by clearance of the radiotracer from brains of WT mice,
thus demonstrating differential retention in regions of
brains, as the agent binds to Aβ plaques in transgenic
mice. Given that initial brain influx would be expected to
be the same in both mouse models, and differential reten-
tion of 18F-7B in transgenic mice could result from its
binding to Aβ plaques and clearance of the unbound
tracer as a function of time, we therefore used dynamic
PET imaging over 1 to 75 min to interrogate regional
localization of 18F-7B within the brains of transgenic and
WT mice. Preliminary microPET/CT imaging indicates a
higher retention of 18F-7B in the frontal cortex of trans-
genic mice compared with their WT age-matched coun-
terparts (Figure 4A,B) indicating its ability to traverse the
BBB and label Aβ plaques in transgenic mice. Similar to
11C-PIB [46, 49] and Florbetaben [45], 18F-7B shows also
considerable retention in extracerebral regions, such as
nasal and eye cavities. Furthermore, coupled with bindingFigure 5 Time-activity curves (TACs) showing kinetics of [18F]-7B obtained
normalized to the average activity measured in those regions between 1 a
retention of the tracer in cortex of transgenic mice compared with its WT cou
profile consistent with binding of the agent ([18F]-7B) with Aβ plaques in tranaffinity and pharmacokinetic profiles of a given imaging
agent, the presentation of different forms (diffuse and
compact forms) of Aβ and the degree of fibrillary plaques
can also impact signal-to-noise ratios (SNRs), thus influ-
encing image quality. Additionally, Florbetaben, PiB, and
Amyvid are known to preferentially bind fibrillary plaques,
while 7A shows binding to both diffuse and fibrillary pla-
ques, though with a lower affinity compared with ap-
proved tracers. Given these variations in targeting profiles
and binding affinity, slightly lower SNR was observed
using microPET imaging. For evaluation of kinetics, time-
activity curves were obtained in the cortex and cerebellum
(reference) regions of transgenic and WT mice (Figure 5).
The data show a consistently higher retention of 18F-7B
(40 min post-injection) in the cortex of transgenic mice
compared to their age-matched WT controls (Figure 5),
and these observations are in accord with other FDA-
approved agents in rodents [44–46]. For further evaluation
of imaging potential of 18F-7B and analysis of SNRs
in vivo, microPET imaging of transgenic mice as a func-
tion of aging profiles is under investigation. Overall,
these PET data show excellent correlation with earlier
studies employing its unlabeled counterpart 7A via multi-
photon imaging [23].
Conclusions
In summary, a heterocyclic PET radiopharmaceutical
18F-7B was synthesized and analytically characterized. Thefrom ROI of transgenic and WT mice. The SUV data were additionally
nd 2 min after injection. The normalized SUV data indicate a higher
nterpart following a clearance of the unbound tracer, a pharmacokinetic
sgenic mice. TG, ; WT, wild type; SUV, Standard Uptake Value.
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able binding to both Aβ1-42 fibrils and AD homogenates,
while also indicating 3.4-fold higher binding affinity for AD
homogenates compared with Aβ1-42 fibrils. The binding af-
finity of 18F-7B with AD homogenates is slightly inferior to
that of Flutemetamol and Florbetapir and comparable to
Florbetaben. 18F-7B demonstrated labeling of Aβ plaques
in cortex of AD brain sections and the binding to Aβ was
inhibited in the presence of its unlabeled counterpart (7A)
indicating specificity of the probe. Pharmacokinetics data
in normal mice indicate a higher initial influx into the
brain, followed by clearance due to a lack of targeted pla-
ques within the brains of normal mice, an important factor
that could determine critical target/background ratios. Fi-
nally, pilot microPET/CT imaging show a sustained higher
retention of 18F-7B in brains of transgenic mice compared
with their WT counterpart, consistent with the binding of
18F-7B to Aβ plaques in transgenic mice thereby support-
ing multiphoton-imaging data (using 7A) reported earlier
[23]. These data provide a platform scaffold for further
optimization to develop PET tracers with enhanced affinity
and specificity for noninvasive assessment of Aβ plaques
and studies of Aβ pathophysiology in vivo.
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